Host immune response in B-cell lymphomas: Friend or foe?

Archivum Immunologiae et Therapiae Experimentalis

Volumn 56, Issue 4, 2008, Pages 245-255

  Juszczyński, Przemysław ^a   Nowak, Jacek ^b   Warzocha, Krzysztof ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Immune escape; Immunoediting; Lymphoma

Indexed keywords

B LYMPHOCYTE RECEPTOR; BETA 2 MICROGLOBULIN; FAS ANTIGEN; FAS LIGAND; GALECTIN 1; INTERLEUKIN 5; PERFORIN; T LYMPHOCYTE RECEPTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GROWTH; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CELL SELECTION; CELLULAR DISTRIBUTION; CHROMOSOME DELETION; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DOWN REGULATION; GENE TARGETING; GRAFT RECIPIENT; HISTOPATHOLOGY; HLA SYSTEM; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; MORBIDITY; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFLAMMATION; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; TUMOR ESCAPE;

EID: 50649119029     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-008-0028-z     Document Type: Review

References (103)

1. Adamashvili I., Kelley R. E., Pressly T. and McDonald J. C. (2005): Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients. Rheumatol. Int., 25, 491-500.
2. Albitar M., Vose J. M., Johnson M. M., Do K. A., Day A., Jilani I., Kantarjian H., Keating M., O'Brien S. M., Verstovsek S., Armitage J. O. and Giles F. J. (2007): Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk. Res., 31, 139-145.
3. Aljurf M. D., Owaidah T. W., Ezzat A., Ibrahim E. and Tbakhi A. (2003): Antigen- and/or immune-driven lymphoproliferative disorders. Ann. Oncol., 14, 1595-1606.
4. Alvaro T., Lejeune M., Salvado M. T., Bosch R., Garcia J. F., Jaen J., Banham A. H., Roncador G., Montalban C. and Piris M. A. (2005): Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res., 11, 1467-1473.
5. Alvaro T., Lejeune M., Salvado M. T., Lopez C., Jaen J., Bosch R. and Pons L. E. (2006): Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncol., 24, 5350-5357.
6. Amiot L., Onno M., Lamy T., Dauriac C., Le Prise P. Y., Fauchet R. and Drenou B. (1998): Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br. J. Haematol., 100, 655-663.
7. Bende R. J., Aarts W. M., Riedl R. G., de Jong D., Pals S. T. and van Noesel C. J. (2005): Among B cell non-hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J. Exp. Med., 201, 1229-1241.
8. Blay J. Y., Voorzanger N., Favrot M., Burdin N., Rousset F. and Banchereau J. (1995): Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large-cell non-Hodgkin's lymphomas. Blood, 86, 4702-4704.
9. Chemnitz J. M., Eggle D., Driesen J., Classen S., Riley J. L., Debey-Pascher S., Beyer M., Popov A., Zander T. and Schultze J. L. (2007): RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. Blood, 110, 3226-3233.
10. Cheng T. Y., Lin J. T., Chen L. T., Shun C. T., Wang H. P., Lin M. T., Wang T. E., Cheng A. L. and Wu M. S. (2006): Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J. Clin. Oncol., 24, 3483-3489.
11. Cohen P. L. and Eisenberg R. A. (1991): Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol., 9, 243-269.
12. Contini P., Ghio M., Merlo A., Poggi A., Indiveri F. and Puppo F. (2005): Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and Calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation. J. Immunol., 175, 7244-7254.
13. Dave S. S., Wright G., Tan B., Rosenwald A., Gascoyne R. D., Chan W. C., Fisher R. I., Braziel R. M., Rimsza L. M., Grogan T. M., Miller T. P., LeBlanc M., Greiner T. C., Weisenburger D. D., Lynch J. C., Vose J., Armitage J. O., Smeland E. B., Kvaloy S., Holte H., Delabie J., Connors J. M., Lansdorp P. M., Ouyang Q., Lister T. A., Davies A. J., Norton A. J., Muller-Hermelink H. K., Ott G., Campo E., Montserrat E., Wilson W. H., Jaffe E. S., Simon R., Yang L., Powell J., Zhao H., Goldschmidt N., Chiorazzi M. and Staudt L. M. (2004): Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med., 351, 2159-2169.
14. Davidson W. F., Giese T. and Fredrickson T. N. (1998): Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med., 187, 1825-1838.
15. De Re V., De Vita S., Gasparotto D., Marzotto A., Carbone A., Ferraccioli G. and Boiocchi M. (2002): Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin's lymphomas. Eur. J. Immunol., 32, 903-910.
16. De Re V., De Vita S., Marzotto A., Rupolo M., Gloghini A., Pivetta B., Gasparotto D., Carbone A. and Boiocchi M. (2000): Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood, 96, 3578-3584.
17. de Wolf-Peeters C., Pittaluga S., Dierlamm J., Wlodarska I. and Van Den Berghe H. (1997): Marginal zone B-cell lymphomas including mucosa-associated lymphoid tissue type lymphoma (MALT), monocytoid B-cell lymphoma and splenic marginal zone cell lymphoma and their relation to the reactive marginal zone. Leuk. Lymphoma, 26, 467-478.
18. Drenou B., Tilanus M., Semana G., Alizadeh M., Birebent B., Grosset J. M., Dias P., van Wichen D., Arts Y., De Santis D., Fauchet R. and Amiot L. (2004): Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas. Br. J. Haematol., 127, 40-49.
19. Du M., Diss T. C., Xu C., Peng H., Isaacson P. G. and Pan L. (1996): Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia, 10, 1190-1197.
20. Dunn-Walters D. K., Boursier L., Spencer J. and Isaacson P. G. (1998): Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. Hum. Pathol., 29, 585-593.
21. Dunn G. P., Bruce A. T., Sheehan K. C., Shankaran V., Uppaluri R., Bui J. D., Diamond M. S., Koebel C. M., Arthur C., White J. M. and Schreiber R. D. (2005): A critical function for type I interferons in cancer immunoediting. Nat. Immunol., 6, 722-729.
22. Dunn G. P., Koebel C. M. and Schreiber R. D. (2006): Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol., 6, 836-848.
23. Dunn G. P., Old L. J. and Schreiber R. D. (2004): The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21, 137-148.
24. Dunn G. P., Old L. J. and Schreiber R. D. (2004): The three Es of cancer immunoediting. Annu. Rev. Immunol., 22, 329-360.
25. Eaton K. A., Ringler S. R. and Danon S. J. (1999): Murine splenocytes induce severe gastritis and delayed-type hypersensitivity and suppress bacterial colonization in Helicobacter pylori-infected SCID mice. Infect. Immun., 67, 4594-4602.
26. Ekstrom-Smedby K. (2006): Epidemiology and etiology of non-Hodgkin lymphoma - a review. Acta Oncol., 45, 258-271.
27. Elpek K. G., Lacelle C., Singh N. P., Yolcu E. S. and Shirwan H. (2007): CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol., 178, 6840-6848.
28. Enzler T., Gillessen S., Manis J. P., Ferguson D., Fleming J., Alt F. W., Mihm M. and Dranoff G. (2003): Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J. Exp. Med., 197, 1213-1219.
29. Farinha P., Masoudi H., Skinnider B. F., Shumansky K., Spinelli J. J., Gill K., Klasa R., Voss N., Connors J. M. and Gascoyne R. D. (2005): Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 106, 2169-2174.
30. Grulich A. E., van Leeuwen M. T., Falster M. O. and Vajdic C. M. (2007): Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet, 370, 59-67.
31. Hasselblom S., Sigurdadottir M., Hansson U., Nilsson-Ehle H., Ridell B. and Andersson P. O. (2007): The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br. J. Haematol., 137, 364-373.
32. Hilchey S. P., De A., Rimsza L. M., Bankert R. B. and Bernstein S. H. (2007): Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. J. Immunol., 178, 4051-4061.
33. Hsiao F. C., Lin M., Tai A., Chen G. and Huber B. T. (2006): Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J. Immunol., 177, 2056-2060.
34. Hsu S. M., Lin J., Xie S. S., Hsu P. L. and Rich S. (1993): Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum. Pathol., 24, 249-255.
35. Hussell T., Isaacson P. G., Crabtree J. E. and Spencer J. (1993): The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet, 342, 571-574.
36. Hviid T. V., Hylenius S., Rorbye C. and Nielsen L. G. (2003): HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics, 55, 63-79.
37. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., Inagaki H. and Ueda R. (2006): Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res., 66, 5716-5722.
38. Juszczynski P., Kalinka E., Bienvenu J., Woszczek G., Borowiec M., Robak T., Kowalski M., Lech-Maranda E., Baseggio L., Coiffier B., Salles G. and Warzocha K. (2002): Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood, 100, 3037-3040.
39. Juszczynski P., Kutok J. L., Li C., Mitra J., Aguiar R. C. and Shipp M. A. (2006): BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Mol. Cell. Biol., 26, 5348-5359.
40. Juszczynski P., Ouyang J., Monti S., Rodig S. J., Takeyama K., Abramson J., Chen W., Kutok J. L., Rabinovich G. A. and Shipp M. A. (2007): The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA, 104, 13134-13139.
41. Katz I. R., Chapman-Alexander J., Jacobson E. B., Lerman S. P. and Thorbecke G. J. (1981): Growth of SJL/J-derived transplantable reticulum cell sarcoma as related to its ability to induce T-cell proliferation in the host. III. Studies on thymectomized and congenitally athymic SJL mice. Cell. Immunol., 65, 84-92.
42. Kawasaki A., Shinkai Y., Yagita H. and Okumura K. (1992): Expression of perforin in murine natural killer cells and cytotoxic T lymphocytes in vivo. Eur. J. Immunol., 22, 1215-1219.
43. Kirszenbaum M., Moreau P., Gluckman E., Dausset J. and Carosella E. (1994): An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc. Natl. Acad. Sci. USA, 91, 4209-4213.
44. Kirszenbaum M., Moreau P., Teyssier M., Lafon C., Gluckman E., Dausset J. and Carosella E. (1995): Evidence for the presence of the alternatively spliced HLA-G mRNA forms in human mononuclear cells from peripheral blood and umbilical cord blood. Hum. Immunol., 43, 237-241.
45. Kuppers R., Klein U., Hansmann M. L. and Rajewsky K. (1999): Cellular origin of human B-cell lymphomas. N. Engl. J. Med., 341, 1520-1529.
46. Lasky J. L. and Thorbecke G. J. (1989): Characterization and growth factor requirements of SJL lymphomas. II. Interleukin 5 dependence of the in vitro cell line, cRCS-X, and influence of other cytokines. Eur. J. Immunol., 19, 365-371.
47. Lech-Maranda E., Baseggio L., Bienvenu J., Charlot C., Berger F., Rigal D., Warzocha K., Coiffier B. and Salles G. (2004): Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood, 103, 3529-3534.
48. Lech-Maranda E., Bienvenu J., Michallet A. S., Houot R., Robak T., Coiffier B. and Salles G. (2006): Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur. Cytokine Netw., 17, 60-66.
49. Lech-Maranda E., Juszczynski P., Szmigielska-Kaplon A., Jamroziak K., Balcerczak E. and Robak T. (2007): Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia? Haematologica, 92, 710-711.
50. LeMaoult J., Krawice-Radanne I., Dausset J. and Carosella E. D. (2004): HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc. Natl. Acad. Sci. USA, 101, 7064-7069.
51. Lerman S. P., Carswell E. A., Chapman J. and Thorbecke G. J. (1976): Properties of reticulum cell sarcomas in SJL/J mice. III. Promotion of tumor growth in irradiated mice by normal lymphoid cells. Cell. Immunol., 23, 53-67.
52. Li Z., Woo C. J., Iglesias-Ussel M. D., Ronai D. and Scharff M. D. (2004): The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev., 18, 1-11.
53. Lila N., Rouas-Freiss N., Dausset J., Carpentier A. and Carosella E. D. (2001): Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc. Natl. Acad. Sci. USA, 98, 12150-12155.
54. Lundin K. U., Hofgaard P. O., Omholt H., Munthe L. A., Corthay A. and Bogen B. (2003): Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood, 102, 605-612.
55. Lundin K. U., Screpanti V., Omholt H., Hofgaard P. O., Yagita H., Grandien A. and Bogen B. (2004): CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol. Immunother., 53, 1135-1145.
56. Marasca R., Vaccari P., Luppi M., Zucchini P., Castelli I., Barozzi P., Cuoghi A. and Torelli G. (2001): Immunoglobulin gene mutations and frequent use of VH1--69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am. J. Pathol., 159, 253-261.
57. Marshall N. A., Christie L. E., Munro L. R., Culligan D. J., Johnston P. W., Barker R. N. and Vickers M. A. (2004): Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood, 103, 1755-1762.
58. Mitra-Kaushik S., Harding J., Hess J., Schreiber R. and Ratner L. (2004): Enhanced tumorigenesis in HTLV-1 taxtransgenic mice deficient in interferon-gamma. Blood, 104, 3305-3311.
59. Mocellin S., Marincola F., Rossi C. R., Nitti D. and Lise M. (2004): The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev., 15, 61-76.
60. Monti S., Savage K. J., Kutok J. L., Feuerhake F., Kurtin P., Mihm M., Wu B., Pasqualucci L., Neuberg D., Aguiar R. C., Dal Cin P., Ladd C., Pinkus G. S., Salles G., Harris N. L., Dalla-Favera R., Habermann T. M., Aster J. C., Golub T. R. and Shipp M. A. (2005): Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 105, 1851-1861.
61. Moreau P., Carosella E., Teyssier M., Prost S., Gluckman E., Dausset J. and Kirszenbaum M. (1995): Soluble HLA-G molecule. An alternatively spliced HLA-G mRNA form candidate to encode it in peripheral blood mononuclear cells and human trophoblasts. Hum. Immunol., 43, 231-236.
62. Morse H. C. 3rd, Kearney J. F., Isaacson P. G., Carroll M., Fredrickson T. N. and Jaffe E. S. (2001): Cells of the marginal zone-origins, function and neoplasia. Leuk. Res., 25, 169-178.
63. Munthe L. A., Corthay A., Os A., Zangani M. and Bogen B. (2005): Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region--specific T cells. J. Immunol., 175, 2391-2400.
64. Muschen M., Rajewsky K., Kronke M. and Kuppers R. (2002): The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol., 23, 75-80.
65. Nowak J., Kalinka-Warzocha E., Juszczynski P., Bilinski P., Mika-Witkowska R., Zajko M., Bienvenu J., Coiffier B., Salles G. and Warzocha K. (2007): Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Genes Chromosomes Cancer, 46, 500-507.
66. Nowak J., Kalinka-Warzocha E., Juszczynski P., Mika-Witkowska R., Zajko M., Graczyk-Pol E., Coiffier B., Salles G. and Warzocha K. (2008): Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. Tissue Antigens, 71, 16-26.
67. Nuckel H., Rebmann V., Durig J., Duhrsen U. and Grosse-Wilde H. (2005): HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood, 105, 1694-1698.
68. Ohshima K., Tutiya T., Yamaguchi T., Suzuki K., Suzumiya J., Kawasaki C., Haraoka S. and Kikuchi M. (2002): Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells. Int. J. Cancer, 98, 567-572.
69. Pappo J., Torrey D., Castriotta L., Savinainen A., Kabok Z. and Ibraghimov A. (1999): Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect. Immun., 67, 337-341.
70. Poppema S., Potters M., Visser L. and van den Berg A. M. (1998): Immune escape mechanisms in Hodgkin's disease. Ann. Oncol., 9 (suppl. 5), S21-24.
71. Rimsza L. M., Roberts R. A., Campo E., Grogan T. M., Bea S., Salaverria I., Zettl A., Rosenwald A., Ott G., Muller-Hermelink H. K., Delabie J., Fisher R. I., Unger J. M., Leblanc M., Staudt L. M., Jaffe E. S., Gascoyne R. D., Chan W. C., Weisenburger D. D., Greiner T., Braziel R. M. and Miller T. P. (2006): Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood, 107, 1101-1107.
72. Rimsza L. M., Roberts R. A., Miller T. P., Unger J. M., LeBlanc M., Braziel R. M., Weisenberger D. D., Chan W. C., Muller-Hermelink H. K., Jaffe E. S., Gascoyne R. D., Campo E., Fuchs D. A., Spier C. M., Fisher R. I., Delabie J., Rosenwald A., Staudt L. M. and Grogan T. M. (2004): Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood, 103, 4251-4258.
73. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R. D., Chan W. C., Zhao T., Haioun C., Greiner T. C., Weisenburger D. D., Lynch J. C., Vose J., Armitage J. O., Smeland E. B., Kvaloy S., Holte H., Delabie J., Campo E., Montserrat E., Lopez-Guillermo A., Ott G., Muller-Hermelink H. K., Connors J. M., Braziel R., Grogan T. M., Fisher R. I., Miller T. P., LeBlanc M., Chiorazzi M., Zhao H., Yang L., Powell J., Wilson W. H., Jaffe E. S., Simon R., Klausner R. D. and Staudt L. M. (2003): Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med., 198, 851-862.
74. Royer B., Cazals-Hatem D., Sibilia J., Agbalika F., Cayuela J. M., Soussi T., Maloisel F., Clauvel J. P., Brouet J. C. and Mariette X. (1997): Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood, 90, 766-775.
75. Rubio-Moscardo F., Blesa D., Mestre C., Siebert R., Balasas T., Benito A., Rosenwald A., Climent J., Martinez J. I., Schilhabel M., Karran E. L., Gesk S., Esteller M., deLeeuw R., Staudt L. M., Fernandez-Luna J. L., Pinkel D., Dyer M. J. and Martinez-Climent J. A. (2005): Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood, 106, 3214-3222.
76. Salles G., Bienvenu J., Bastion Y., Barbier Y., Doche C., Warzocha K., Gutowski M. C., Rieux C. and Coiffier B. (1996): Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br. J. Haematol., 93, 352-359.
77. Sebti Y., Le Maux A., Gros F., De Guibert S., Pangault C., Rouas-Freiss N., Bernard M. and Amiot L. (2007): Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br. J. Haematol., 138, 202-212.
78. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J. and Schreiber R. D. (2001): IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107-1111.
79. Sharpe A. H., Wherry E. J., Ahmed R. and Freeman G. J. (2007): The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol., 8, 239-245.
80. Smyth M. J., Ortaldo J. R., Shinkai Y., Yagita H., Nakata M., Okumura K. and Young H. A. (1990): Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells. J. Exp. Med., 171, 1269-1281.
81. Smyth M. J., Thia K. Y., Street S. E., MacGregor D., Godfrey D. I. and Trapani J. A. (2000): Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med., 192, 755-760.
82. Spaggiari G. M., Contini P., Carosio R., Arvigo M., Ghio M., Oddone D., Dondero A., Zocchi M. R., Puppo F., Indiveri F. and Poggi A. (2002): Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood, 99, 1706-1714.
83. Stasi R., Zinzani P. L., Galieni P., Lauta V. M., Damasio E., Dispensa E., Dammacco F., Papa G. and Tura S. (1994): Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br. J. Haematol., 88, 770-777.
84. Stopeck A. T., Gessner A., Miller T. P., Hersh E. M., Johnson C. S., Cui H., Frutiger Y. and Grogan T. M. (2000): Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin. Cancer Res., 6, 3904-3909.
85. Straus S. E., Jaffe E. S., Puck J. M., Dale J. K., Elkon K. B., Rosen-Wolff A., Peters A. M., Sneller M. C., Hallahan C. W., Wang J., Fischer R. E., Jackson C. M., Lin A. Y., Baumler C., Siegert E., Marx A., Vaishnaw A. K., Grodzicky T., Fleisher T. A. and Lenardo M. J. (2001): The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood, 98, 194-200.
86. Street S. E., Hayakawa Y., Zhan Y., Lew A. M., MacGregor D., Jamieson A. M., Diefenbach A., Yagita H., Godfrey D. I. and Smyth M. J. (2004): Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med., 199, 879-884.
87. Street S. E., Trapani J. A., MacGregor D. and Smyth M. J. (2002): Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med., 196, 129-134.
88. Sutkowski N., Conrad B., Thorley-Lawson D. A. and Huber B. T. (2001): Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity, 15, 579-589.
89. Tierens A., Delabie J., Michiels L., Vandenberghe P. and De Wolf-Peeters C. (1999): Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. Blood, 93, 226-234.
90. Tsiagbe V. K., Asakawa J., Miranda A., Sutherland R. M., Paterson Y. and Thorbecke G. J. (1993): Syngeneic response to SJL follicular center B cell lymphoma (reticular cell sarcoma) cells is primarily in V beta 16+ CD4+ T cells. J. Immunol., 150, 5519-5528.
91. Tsiagbe V. K., Yoshimoto T., Asakawa J., Cho S. Y., Meruelo D. and Thorbecke G. J. (1993): Linkage of superantigen-like stimulation of syngeneic T cells in a mouse model of follicular center B cell lymphoma to transcription of endogenous mammary tumor virus. EMBO J., 12, 2313-2320.
92. Warzocha K., Bienvenu J., Ribeiro P., Moullet I., Dumontet C., Neidhardt-Berard E. M., Coiffier B. and Salles G. (1998): Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br. J. Cancer, 77, 2357-2362.
93. Warzocha K., Ribeiro P., Bienvenu J., Roy P., Charlot C., Rigal D., Coiffier B. and Salles G. (1998): Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood, 91, 3574-3581.
94. Warzocha K., Salles G., Bienvenu J., Barbier Y., Bastion Y., Doche C., Rieux C. and Coiffier B. (1997): Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. Leukemia, 11 (suppl. 3), 441-443.
95. Warzocha K., Salles G., Bienvenu J., Bastion Y., Dumontet C., Renard N., Neidhardt-Berard E. M. and Coiffier B. (1997): Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J. Clin. Oncol., 15, 499-508.
96. Yamamoto R., Nishikori M., Kitawaki T., Sakai T., Hishizawa M., Tashima M., Kondo T., Ohmori K., Kurata M., Hayashi T. and Uchiyama T. (2008): PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood, 111, 3220-3224.
97. Yang Z. Z., Novak A. J., Stenson M. J. Witzig T. E. and Ansell S. M. (2006): Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood, 107, 3639-3646.
98. Yang Z. Z., Novak A. J., Ziesmer S. C., Witzig T. E. and Ansell S. M. (2006): Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res., 66, 10145-10152.
99. Zangani M. M., Froyland M., Qiu G. Y., Meza-Zepeda L. A., Kutok J. L., Thompson K. M., Munthe L. A. and Bogen B. (2007): Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J. Exp. Med., 204, 1181-1191.
100. Zavazava N. (1998): Soluble HLA class I molecules: biological significance and clinical implications. Mol. Med. Today, 4, 116-121.
101. Zavazava N. and Kronke M. (1996): Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat. Med., 2, 1005-1010.
102. Zerafa N., Westwood J. A., Cretney E., Mitchell S., Waring P., Iezzi M., and Smyth M. J. (2005): Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol., 175, 5586-5590.
103. Zhang J. Q., Okumura C., McCarty T., Shin M. S., Mukhopadhyay P., Hori M., Torrey T. A., Naghashfar Z., Zhou J. X., Lee C. H., Roopenian D. C., Morse H. C. 3rd and Davidson W. F. (2004): Evidence for selective transformation of autoreactive immature plasma cells in mice deficient in Fasl. J. Exp. Med., 200, 1467-1478.